Clinical
Higher-Cost Specialty Therapies Make a Move Toward Front-Line Status
Specialty therapies like IL-23 and JAK inhibitors are moving into earlier treatment lines, reshaping care and ...
APRIL 24, 2026
Radiopharmaceuticals Shine in Detecting, Treating Cancer
Radiopharmaceuticals are reshaping cancer care—experts discuss growth, costs, access, and managed care ...
APRIL 22, 2026
The Promise and Pain of GLP-1s on Tap at AMCP Nexus
Glucagon-like peptide-1 drugs were a hot topic at AMCP Nexus 2025, with three presentations spotlighting the ...
APRIL 21, 2026
HOPA 2026: Emerging Off-Tumor Toxicities in CAR-T
Dr. Rebecca Gonzales discusses the incidence and mechanisms of novel toxicities due to off-tumor binding that may ...
APRIL 21, 2026
High-Dose Opioids in Cancer Yield Poor Clinical and Financial Outcomes
High-dose opioid therapy in disease-free cancer survivors is significantly cost-inefficient and associated with ...
APRIL 20, 2026
Navigating Treatment for Huntington's Disease (Part 5)
In Part 5, Dr. Erin Furr-Stimming discusses how to balance cautious optimism for disease-modifying therapies and ...
APRIL 16, 2026
HOPA 2026: Updates in Small Cell Lung Cancer
Dr. Katie O’Reilly provides an update on treatments for both limited and extensive stages of small cell lung ...
APRIL 13, 2026
Pharmacists Are Critical In Opioid Use Disorder Care
Pharmacist opioid use disorder training expands access to buprenorphine treatment, highlighting personalized care ...
APRIL 13, 2026
GLP–1s for Pediatric Obesity: Worth a Shot?
GLP-1 agonists for adolescent obesity spark debate over safety, insurance coverage, and long-term pediatric ...
APRIL 11, 2026
What It Takes to Deliver Anti-Amyloid Alzheimer’s Rx in Real-World Practice
Alzheimer’s anti-amyloid therapy implementation challenges—staffing, imaging, pharmacist roles, and ...
APRIL 10, 2026
The Nuanced Art of Antiplatelet Reversal
Antiplatelet therapy reversal in neurocritical care—testing limits, risks, and new options like bentracimab ...
APRIL 9, 2026
Managing Tardive Dyskinesia (Part 5)
In part 5 of the conversation, Swati Pradeep, DO discusses the real world impacts of Tardive Dyskinesia on ...
APRIL 9, 2026
